Fontan手术前单心室辅助装置(sVAD)对功能性单心室循环患者的支持

Q2 Medicine
Mark S. Bleiweis MD, Joseph Philip MD, FAAP, James C. Fudge MD, Himesh V. Vyas MD, Giles J. Peek MD, FRCS, CTh, FFICM, Andrew D. Pitkin MBBS, MRCP, FRCA, Gregory M. Janelle MD, FASE, FASA, Kevin J. Sullivan MD, Yuriy Stukov MD, Connie S. Nixon RN, Omar M. Sharaf BS, Dan Neal MS, Jeffrey P. Jacobs MD, FACS, FACC, FCCP
{"title":"Fontan手术前单心室辅助装置(sVAD)对功能性单心室循环患者的支持","authors":"Mark S. Bleiweis MD,&nbsp;Joseph Philip MD, FAAP,&nbsp;James C. Fudge MD,&nbsp;Himesh V. Vyas MD,&nbsp;Giles J. Peek MD, FRCS, CTh, FFICM,&nbsp;Andrew D. Pitkin MBBS, MRCP, FRCA,&nbsp;Gregory M. Janelle MD, FASE, FASA,&nbsp;Kevin J. Sullivan MD,&nbsp;Yuriy Stukov MD,&nbsp;Connie S. Nixon RN,&nbsp;Omar M. Sharaf BS,&nbsp;Dan Neal MS,&nbsp;Jeffrey P. Jacobs MD, FACS, FACC, FCCP","doi":"10.1053/j.pcsu.2022.12.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>Some patients with functionally univentricular circulation develop cardiac failure refractory to maximal management and are supported with a ventricular assist device<span> (VAD). The purpose of this manuscript is to summarize our previous publications related to single ventricle-ventricular assist device (sVAD) support in patients<span> with functionally univentricular circulation and to describe our current institutional approach at University of Florida to sVAD support in neonates, infants, and children prior to Fontan. Our programmatic philosophy at University of Florida is to strive to identify the minority of neonates with functionally univentricular circulation who are extremely high-risk prior to initiating staged palliation and to stabilize these neonates with primary preemptive sVAD in preparation for </span></span></span>cardiac transplantation; our rationale for this approach is related to the challenges associated with failed staged palliation and subsequent bail-out sVAD support and transplantation. A subset of extremely high-risk neonates and infants with functionally univentricular ductal-dependent circulation undergo primary preemptive sVAD insertion and subsequent cardiac transplantation. Support with VAD clearly facilitates survival on the waiting list during prolonged wait times and optimizes outcomes after Norwood (Stage 1) by providing an alternative pathway for extremely high-risk patients. Therefore, the selective utilization of sVAD in extremely high-risk neonates facilitates improved outcomes for all patients with functionally univentricular ductal-dependent circulation.</p><p><span>At University of Florida, our programmatic approach to utilizing sVAD support as a bridge to transplantation in the minority of neonates with functionally univentricular circulation who are extremely high-risk for staged palliation is associated with Operative Mortality after Norwood (Stage 1) Operation of 2.9% (2/68) and a one-year survival of 91.1% (82/90) for all neonates presenting with </span>hypoplastic left heart syndrome<span><span> (HLHS) or HLHS-related malformation with functionally univentricular ductal-dependent </span>systemic circulation.</span></p><p>Meanwhile, at University of Florida, for all 82 consecutive neonates, infants, and children supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 73.3% (95% confidence interval [CI] = 64.1–83.8%), and Kaplan-Meier survival estimated five years after VAD insertion = 68.3% (95% CI = 58.4–79.8%). For all 48 consecutive neonates, infants, and children at University of Florida with biventricular circulation supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 82.7% (95% CI = 72.4–94.4%), and Kaplan-Meier survival estimated five years after VAD insertion = 79.7% (95% CI = 68.6–92.6%). For all 34 consecutive neonates, infants, and children at University of Florida with functionally univentricular circulation supported with pulsatile paracorporeal sVAD: Kaplan-Meier survival estimated one year after VAD insertion = 59.7% (95% CI = 44.9–79.5%), and Kaplan-Meier survival estimated five years after VAD insertion = 50.5% (95% CI = 35.0–73.0%). These Kaplan-Meier survival estimates for patients supported with pulsatile paracorporeal VAD are better in patients with biventricular circulation in comparison to patients with functionally univentricular circulation both one year after VAD insertion (P=0.026) and five years after VAD insertion (P=0.010).</p><p>Although outcomes after VAD support in functionally univentricular patients are worse than in patients with biventricular circulation, sVAD provides a reasonable chance for survival. Ongoing research is necessary to improve the outcomes of these challenging patients, with the goal of developing strategies where outcomes after sVAD support in functionally univentricular patients are equivalent to the outcomes achieved after VAD support in patients with biventricular circulation.</p></div>","PeriodicalId":38774,"journal":{"name":"Pediatric Cardiac Surgery Annual","volume":"26 ","pages":"Pages 26-39"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Support with Single Ventricle-Ventricular Assist Device (sVAD) in Patients with Functionally Univentricular Circulation Prior to Fontan Operation\",\"authors\":\"Mark S. Bleiweis MD,&nbsp;Joseph Philip MD, FAAP,&nbsp;James C. Fudge MD,&nbsp;Himesh V. Vyas MD,&nbsp;Giles J. Peek MD, FRCS, CTh, FFICM,&nbsp;Andrew D. Pitkin MBBS, MRCP, FRCA,&nbsp;Gregory M. Janelle MD, FASE, FASA,&nbsp;Kevin J. Sullivan MD,&nbsp;Yuriy Stukov MD,&nbsp;Connie S. Nixon RN,&nbsp;Omar M. Sharaf BS,&nbsp;Dan Neal MS,&nbsp;Jeffrey P. Jacobs MD, FACS, FACC, FCCP\",\"doi\":\"10.1053/j.pcsu.2022.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Some patients with functionally univentricular circulation develop cardiac failure refractory to maximal management and are supported with a ventricular assist device<span> (VAD). The purpose of this manuscript is to summarize our previous publications related to single ventricle-ventricular assist device (sVAD) support in patients<span> with functionally univentricular circulation and to describe our current institutional approach at University of Florida to sVAD support in neonates, infants, and children prior to Fontan. Our programmatic philosophy at University of Florida is to strive to identify the minority of neonates with functionally univentricular circulation who are extremely high-risk prior to initiating staged palliation and to stabilize these neonates with primary preemptive sVAD in preparation for </span></span></span>cardiac transplantation; our rationale for this approach is related to the challenges associated with failed staged palliation and subsequent bail-out sVAD support and transplantation. A subset of extremely high-risk neonates and infants with functionally univentricular ductal-dependent circulation undergo primary preemptive sVAD insertion and subsequent cardiac transplantation. Support with VAD clearly facilitates survival on the waiting list during prolonged wait times and optimizes outcomes after Norwood (Stage 1) by providing an alternative pathway for extremely high-risk patients. Therefore, the selective utilization of sVAD in extremely high-risk neonates facilitates improved outcomes for all patients with functionally univentricular ductal-dependent circulation.</p><p><span>At University of Florida, our programmatic approach to utilizing sVAD support as a bridge to transplantation in the minority of neonates with functionally univentricular circulation who are extremely high-risk for staged palliation is associated with Operative Mortality after Norwood (Stage 1) Operation of 2.9% (2/68) and a one-year survival of 91.1% (82/90) for all neonates presenting with </span>hypoplastic left heart syndrome<span><span> (HLHS) or HLHS-related malformation with functionally univentricular ductal-dependent </span>systemic circulation.</span></p><p>Meanwhile, at University of Florida, for all 82 consecutive neonates, infants, and children supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 73.3% (95% confidence interval [CI] = 64.1–83.8%), and Kaplan-Meier survival estimated five years after VAD insertion = 68.3% (95% CI = 58.4–79.8%). For all 48 consecutive neonates, infants, and children at University of Florida with biventricular circulation supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 82.7% (95% CI = 72.4–94.4%), and Kaplan-Meier survival estimated five years after VAD insertion = 79.7% (95% CI = 68.6–92.6%). For all 34 consecutive neonates, infants, and children at University of Florida with functionally univentricular circulation supported with pulsatile paracorporeal sVAD: Kaplan-Meier survival estimated one year after VAD insertion = 59.7% (95% CI = 44.9–79.5%), and Kaplan-Meier survival estimated five years after VAD insertion = 50.5% (95% CI = 35.0–73.0%). These Kaplan-Meier survival estimates for patients supported with pulsatile paracorporeal VAD are better in patients with biventricular circulation in comparison to patients with functionally univentricular circulation both one year after VAD insertion (P=0.026) and five years after VAD insertion (P=0.010).</p><p>Although outcomes after VAD support in functionally univentricular patients are worse than in patients with biventricular circulation, sVAD provides a reasonable chance for survival. Ongoing research is necessary to improve the outcomes of these challenging patients, with the goal of developing strategies where outcomes after sVAD support in functionally univentricular patients are equivalent to the outcomes achieved after VAD support in patients with biventricular circulation.</p></div>\",\"PeriodicalId\":38774,\"journal\":{\"name\":\"Pediatric Cardiac Surgery Annual\",\"volume\":\"26 \",\"pages\":\"Pages 26-39\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Cardiac Surgery Annual\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1092912622000187\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Cardiac Surgery Annual","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1092912622000187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

一些功能性单心室循环的患者出现无法最大限度治疗的心力衰竭,并得到心室辅助装置(VAD)的支持。本手稿的目的是总结我们以前关于功能性单心室循环患者单心室辅助装置(sVAD)支持的出版物,并描述我们目前在佛罗里达大学对Fontan之前新生儿、婴儿和儿童的sVAD支持的机构方法。我们在佛罗里达大学的计划理念是努力确定少数患有功能性单心室循环的新生儿,他们在开始阶段性缓解之前具有极高的风险,并在准备心脏移植时用初次预防性sVAD稳定这些新生儿;我们采用这种方法的理由与阶段性缓解失败以及随后的sVAD支持和移植纾困相关的挑战有关。一组极高危新生儿和功能性单心室导管依赖性循环的婴儿接受了初次抢先sVAD插入和随后的心脏移植。VAD的支持显然有助于在长时间等待期间在等待名单上存活,并通过为高危患者提供替代途径优化诺伍德(第1阶段)后的结果。因此,在高危新生儿中选择性使用sVAD有助于改善所有功能性单心室导管依赖性循环患者的预后。在佛罗里达大学,我们利用sVAD支持作为少数功能性单心室循环新生儿移植的桥梁,这些新生儿极易分期缓解,诺伍德(1期)手术后的手术死亡率为2.9%(2/68),所有左心发育不全的新生儿一年生存率为91.1%(82/90)综合征(HLHS)或具有功能性单心室导管依赖性系统循环的HLHS相关畸形。同时,在佛罗里达大学,对于所有连续82例接受搏动性体外VAD支持的新生儿、婴儿和儿童:VAD插入后一年的Kaplan-Meier生存率估计为73.3%(95%置信区间[CI]=64.1-83.8%),VAD插入前五年的Kaplan-Meier存率估计为68.3%(95%可信区间=58.4-79.8%),佛罗里达大学双心室循环支持搏动性体外VAD的儿童:VAD插入后一年的Kaplan-Meier生存率估计为82.7%(95%CI=72.4-94.4%),佛罗里达大学的儿童使用脉动体外sVAD支持功能性单心室循环:VAD插入后一年的Kaplan-Meier生存率估计为59.7%(95%CI=44.9-79.5%),VAD植入后五年的Kaplan-Meier生存率估计值为50.5%(95%可信区间为35.0-73.0%)。与功能性单心室循环患者相比,双心室循环患者在VAD植入一年后(P=0.026)和VAD植入五年后的Kaplan-Maier生存率估计值更高(P=0.010)。尽管功能性单心室患者在VAD支持后的结果比双心室循环患者更差,但sVAD提供了合理的生存机会。为了改善这些具有挑战性的患者的结果,有必要进行持续的研究,目的是制定策略,使功能性单心室患者的sVAD支持后的结果与双心室循环患者的VAD支持前的结果相等。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Support with Single Ventricle-Ventricular Assist Device (sVAD) in Patients with Functionally Univentricular Circulation Prior to Fontan Operation

Some patients with functionally univentricular circulation develop cardiac failure refractory to maximal management and are supported with a ventricular assist device (VAD). The purpose of this manuscript is to summarize our previous publications related to single ventricle-ventricular assist device (sVAD) support in patients with functionally univentricular circulation and to describe our current institutional approach at University of Florida to sVAD support in neonates, infants, and children prior to Fontan. Our programmatic philosophy at University of Florida is to strive to identify the minority of neonates with functionally univentricular circulation who are extremely high-risk prior to initiating staged palliation and to stabilize these neonates with primary preemptive sVAD in preparation for cardiac transplantation; our rationale for this approach is related to the challenges associated with failed staged palliation and subsequent bail-out sVAD support and transplantation. A subset of extremely high-risk neonates and infants with functionally univentricular ductal-dependent circulation undergo primary preemptive sVAD insertion and subsequent cardiac transplantation. Support with VAD clearly facilitates survival on the waiting list during prolonged wait times and optimizes outcomes after Norwood (Stage 1) by providing an alternative pathway for extremely high-risk patients. Therefore, the selective utilization of sVAD in extremely high-risk neonates facilitates improved outcomes for all patients with functionally univentricular ductal-dependent circulation.

At University of Florida, our programmatic approach to utilizing sVAD support as a bridge to transplantation in the minority of neonates with functionally univentricular circulation who are extremely high-risk for staged palliation is associated with Operative Mortality after Norwood (Stage 1) Operation of 2.9% (2/68) and a one-year survival of 91.1% (82/90) for all neonates presenting with hypoplastic left heart syndrome (HLHS) or HLHS-related malformation with functionally univentricular ductal-dependent systemic circulation.

Meanwhile, at University of Florida, for all 82 consecutive neonates, infants, and children supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 73.3% (95% confidence interval [CI] = 64.1–83.8%), and Kaplan-Meier survival estimated five years after VAD insertion = 68.3% (95% CI = 58.4–79.8%). For all 48 consecutive neonates, infants, and children at University of Florida with biventricular circulation supported with pulsatile paracorporeal VAD: Kaplan-Meier survival estimated one year after VAD insertion = 82.7% (95% CI = 72.4–94.4%), and Kaplan-Meier survival estimated five years after VAD insertion = 79.7% (95% CI = 68.6–92.6%). For all 34 consecutive neonates, infants, and children at University of Florida with functionally univentricular circulation supported with pulsatile paracorporeal sVAD: Kaplan-Meier survival estimated one year after VAD insertion = 59.7% (95% CI = 44.9–79.5%), and Kaplan-Meier survival estimated five years after VAD insertion = 50.5% (95% CI = 35.0–73.0%). These Kaplan-Meier survival estimates for patients supported with pulsatile paracorporeal VAD are better in patients with biventricular circulation in comparison to patients with functionally univentricular circulation both one year after VAD insertion (P=0.026) and five years after VAD insertion (P=0.010).

Although outcomes after VAD support in functionally univentricular patients are worse than in patients with biventricular circulation, sVAD provides a reasonable chance for survival. Ongoing research is necessary to improve the outcomes of these challenging patients, with the goal of developing strategies where outcomes after sVAD support in functionally univentricular patients are equivalent to the outcomes achieved after VAD support in patients with biventricular circulation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
7
期刊介绍: The Pediatric Cardiac Surgery Annual is a companion to Seminars in Thoracic and Cardiovascular Surgery . Together with the Seminars, the Annual provides complete coverage of the specialty by focusing on important developments in pediatric cardiac surgery. Each annual volume has an expert guest editor who invites prominent surgeons to review the areas of greatest change in pediatric cardiac surgery during the year. Topics include 1) Complete Atrioventricular Canal; 2) New Concepts of Cardiac Anatomy and Function -- The Helical Heart; 3) Valve Reconstruction (Replacement) in Congenital Heart Disease; 4) Evolving Developments in Congenital Heart Surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信